|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| REVENUE | |||
| Other operating income, net | |||
| General and administrative expense | |||
| Research and development expenses | |||
| Total operating loss | |||
| Other income and gains | |||
| Other (expenses)/income | |||
| Investment income | |||
| Fair value gain on financial assets at fair value through profit or loss ("FVTPL") | |||
| Share of loss of investments accounted for using the equity method | |||
| Fair value loss on financial liabilities at FVTPL | |||
| Fair value (loss)/gain on financial liabilities at FVTPL | |||
| Finance costs | |||
| LOSS BEFORE TAX | |||
| Income tax expense | |||
| LOSS FOR THE YEAR | |||
| Attributable to: | |||
| Ordinary Equity Holders of the Parent | |||
| Items that may be reclassified to profit or loss | |||
| Exchange differences on translation of the financial statements of subsidiaries | |||
| Other comprehensive (loss)/income for the year, net of tax | |||
| TOTAL COMPREHENSIVE LOSS FOR THE YEAR | |||
| LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT | |||
| Basic loss for the year (in Dollars per share) | |||
| Diluted loss for the year (in Dollars per share) | |||
| Weighted average common shares outstanding, basic (in Shares) | |||
| Weighted average common shares outstanding, diluted (in Shares) |
Loading...
